LIAN News and Press, LianBio From 03/10/22

SHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Following the Determination Report of the Public Company Accounting Oversight Board (“PCAOB”) issued on December 16, 2021, on March 8, 2022 the U.S. Securities and Exchange Commission (the “SEC”) re...

The company is focused on bringing innovative therapies to China and major Asian markets through partnerships with other biotech/pharma companies. China is the second-largest pharmaceutical market in the world ($220 billion/year), after the U.S. The stock is significantly underval...

LianBio (NASDAQ:LIAN) said the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted breakthrough therapy designation in China for mavacamten to treat patients with obstructive hypertrophic cardiomyopathy (oHCM). Hypertrophic cardiomyopathy is a ...

SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the National Medical Pr...

SHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in the Phase 3 EXPLORER-CN c...

SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that infigratinib has been approved by the Health Commission ...

LianBio (NASDAQ:LIAN): Q3 GAAP EPS of -$0.63 misses by $0.28. Cash and cash equivalents were $109M Press Release For further details see: LianBio EPS misses by $0.28

Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers Initiated Phase 2a clinical trial of infigratinib in Chinese patients with gastric cancer and other advanced solid tumors Strengthened leadership team with appointmen...

Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO. Hotel operator Atour makes similar updated filing for U.S. IPO plan to raise $350 million, valuing the company at more than $2 billion. LianBio's s...